Respirology

According to the 2023 Canadian Thoracic Society guidelines on pharmacotherapy in patients with stable COPD, all the following statements are true, EXCEPT for . . .

Canadian Thoracic Society issues updated recommendations and a revised treatment pathway to optimize maintenance pharmacologic therapy in stable COPD.

Study provides insight on the value of a new orally-administered, selective P2X3 receptor antagonist antitussive that is under review by Health Canada.

The cocktail of antibodies soothes respiratory symptoms caused by COVID-19 during its acute phase.

With Alberta and other regions experiencing pertussis outbreaks, you may be more likely to see cases of this vaccine-preventable illness in your clinic or emergency department. Test your knowledge here.

This continuing education lesson discusses practical approaches for pharmacy teams to help COPD and asthma patients improve control of their lung condition.

Few studies have assessed blood gases and acid-base status during the wearing of surgical mask or N95s.

Designed for healthcare professionals to learn about the health effects of wildfire smoke and educate their patients on actions that can reduce exposure.